Aveloxi Tablet 400 mg

Composition:

Each film-coated tablet contains 400 mg of moxifloxacin (as hydrochloride).
Contains 68 mg of lactose monohydrate per tablet.

Indications:

Indicated for the treatment of the following bacterial infections caused by susceptible strains:

• Respiratory tract infections

• Exacerbation of chronic bronchitis

• Community-acquired pneumonia, including cases caused by multi-drug resistant strains

• Acute sinusitis

• Uncomplicated skin and skin structure infections

• Uncomplicated pelvic inflammatory disease (e.g., upper genital tract infections in women including salpingitis and endometritis)

• Complicated skin and skin structure infections (including diabetic foot infections)

• Complicated intra-abdominal infections, including polymicrobial infections such as abscesses

Dosage:

The recommended dose of Aveloxi is 400 mg once daily.

The film-coated tablet should be swallowed whole with sufficient liquid, independently of food intake.

The duration of treatment should be determined based on severity or clinical response. The following general recommendations exist for upper and lower respiratory tract infections:

• Bronchitis: Exacerbation of chronic bronchitis, 5 days

• Pneumonia: Community-acquired pneumonia, 10 days

• Sinusitis: Acute sinusitis, 7 days

• Uncomplicated skin and skin structure infections: 7 days

• Uncomplicated pelvic inflammatory disease: 14 days

• Complicated skin and skin structure infections:
  Total duration of therapy after intravenous or oral treatment: 7–21 days

• Complicated intra-abdominal infections:
  Total duration of therapy after intravenous and oral treatment: 5–14 days

Storage:

Store at a temperature not exceeding 30°C. Keep in the original packaging and container.
Keep out of reach of children.
Shelf life: tablets – 4 years.